ChromaDex Initiates Second Human Clinical Study for its Caffeine Ingredient, PURENERGY
date:May 15, 2014
other metabolic functions. The findings from the first clinical trial of the pure compound, which were presented in September 2012 at the American Heart Association's High Blood Pressure Research 2012 Scientific Sessions, showed that pTeroPure (pterostilbene) significantly reduced blood pressure in adults. pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost Sullivan.
6/6 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
07/12 09:22